Inflammation and neurodegeneration in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 10, Issue SUPPL. 1, 2004, Pages S3-

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

C reactive protein; Complement; Cytokines; Immunohistochemistry; Microglia; mRNA

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BRAIN REGION; CELL ACTIVATION; CELL DEATH; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; DISEASE MODEL; EXPOSURE; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MICROGLIA; MONKEY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; UPREGULATION;

EID: 1942454250     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2004.01.005     Document Type: Conference Paper

References (41)

1. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 27:2003;741-749.
2. McGeer P.L., Yasojima K., McGeer E.G. Inflammation in Parkinson's disease. Adv Neurol. 86:2001;83-89.
3. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci. 991:2003;214-228.
4. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci. 991:2003;120-131.
5. Wullner U., Klockgether T. Inflammation in Parkinson's disease. J Neurol. 250:(Suppl 1):2003;I35-I38.
6. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson's disease. Prog Neurobiol. 68:(5):2002;325-340.
7. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 304:2003;1-7.
8. Chen H., Zhang S.M., Herman M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., Acherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 60:2003;1059-1064.
9. Le WD, Rowe DB, Xie W. Activated microglia induce dopaminergic cell injury in vitro. XIII International Congress on Parkinson's Disease, 1999; S19.
10. Gao H.M., Hong J.S., Zhang W., Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci. 23:2003;1228-1236.
11. Chung E.S., Joe E.H., Ryu J.K., Kim J., Lee Y.B., Cho K.G., Oh Y.J., Maeng S.H., Baik H.H., Kim S.U., Jin B.K. GT1b ganglioside induces death of dopaminergic neurons in rat mesencephalic cultures. Neuroreport. 12:2001;611-614.
12. Gao H.M., Hong J.S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 22:2002;782-790.
13. He Y., Le W.D., Appel S.H. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp Neurol. 176:2002;322-327.
14. Yamada T., McGeer P.L., McGeer E.G. Relationship of complement-activated oligodendrocytes to reactive microglia and neuronal pathology in neurodegenerative disease. Dementia. 2:1991;71-77.
15. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
16. Yamada T., McGeer E.G., Schelper R.L., Wszolek Z.K., McGeer P.L., Pfeiffer R.F., Rodnitzky R.L. Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia. Neurol Psychiatry Brain Res. 2:1993;26-35.
17. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 46:1999;598-605.
18. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,4- tetrahydropyridine administration. Ann Neurol. 54:2003;599-604.
19. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Upregulated production and activation of the complement system in Alzheimer disease brain. Am J Pathol. 154:1999;927-936.
20. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 53:(Suppl 3):2003;S26-S36.
21. Koutsilieri E., Scheller C., Grunblatt E., Nara K., Li J., Riederer P. Free radicals in Parkinson's disease. J Neurol. 249:(Suppl 2):2002;II1-II5.
22. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 15:2002;991-998.
23. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., Beal M.F., Volpe B.T., Joh T.H. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964:2003;288-294.
24. Gao H.M., Liu B., Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 23:(15):2003;6181-6187.
25. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett. 341:2003;87-90.
26. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis. 12:2003;35-45.
27. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 110:2002;49-58.
28. Ryu J.K., Shin W.H., Kim J., Joe E.H., Lee Y.B., Cho K.G., Oh Y.J., Kim S.U., Jin B.K. Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia. 38:2002;15-23.
29. Walker D.G., Lue L.-F., Klegeris A., McGeer P.L. The involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer's disease. Rogers J. Neuroinflammatory mechanisms in Alzheimer's disease: basic and clinical research. 2001;173-195 Birkhauser, Basel.
30. Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., Bader M.F. Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J Biol Chem. 273:1998;14339-14346.
31. Yasuhara O., Kawamata T., Aimi Y., McGeer E.G., McGeer P.L. Expression of chromogranin A in lesions of the central nervous system from patients with neurological diseases. Neurosci Lett. 170:1994;13-16.
32. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 17:2003;500-502.
33. Aimi Y., McGeer P.L. Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinsonism Relat Disord. 2:1996;69-74.
34. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-a (TNF-a) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 165:1994;208-210.
35. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett. 172:1994;151-154.
36. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., Hirsch E.C. Fc epsilon RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 19:1999;3440-3447.
37. McGeer P.L., Yasojima K., McGeer E.G. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett. 326:2002;67-69.
38. Schulte T., Schols L., Muller T., Woitalla D., Berger K., Kruger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett. 326:2002;70-72.
39. Gayle D.A., Ling Z.D., Tong C.W., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-a, interleukin-1b, and nitric oxide. Dev Brain Res. 133:2002;27-36.
40. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16:2002;1474-1476.
41. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. 84:1992;100-104.